Placebo + Sevelamer carbonate

Phase 2Completed
0 watching 0 views this week Active
51
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hyperphosphatemia

Conditions

Hyperphosphatemia, Chronic Kidney Disease

Trial Timeline

May 1, 2012 → Jun 1, 2015

About Placebo + Sevelamer carbonate

Placebo + Sevelamer carbonate is a phase 2 stage product being developed by Sanofi for Hyperphosphatemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01574326. Target conditions include Hyperphosphatemia, Chronic Kidney Disease.

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
5
Community
5

Clinical Trials (3)

NCT IDPhaseStatus
NCT01574326Phase 2Completed
NCT01220843Phase 3Completed
NCT01736150Phase 3Completed

Competing Products

20 competing products in Hyperphosphatemia

See all competitors
ProductCompanyStageHype Score
EOS789 + Placebo + RenvelaChugai PharmaceuticalPhase 1
33
DS-2330b PIB + Placebo + Sevelamer + DS-2330b TabletDaiichi SankyoPhase 1
33
ASP1585 + Placebo + Sevelamer hydrochlorideAstellas PharmaPhase 2
52
ASP1585Astellas PharmaPhase 2
52
the standard-dose group (4 g/day)Kyowa KirinPre-clinical
23
KHK7791 + PlacebpKyowa KirinPhase 2
52
KHK7791Kyowa KirinPhase 2
52
KHK7791 + PlaceboKyowa KirinPhase 3
77
the low-dose group (1.5 g/day) or the standard-dose group (4 g/day)Kyowa KirinPre-clinical
23
KHK7791 + PlaceboKyowa KirinPhase 3
77
KHK7791Kyowa KirinPhase 3
77
KHK7791 + PlaceboKyowa KirinPhase 2
52
KHK7791Kyowa KirinPhase 3
77
SBR759 + Sevelamer HCl + SBR759 + Sevelamer HClNovartisPhase 2
52
SBR759A + SBR759A + SBR759A + SBR759A + SBR759ANovartisPhase 3
77
PA21Kissei PharmaceuticalPhase 3
76
Placebo + Sevelamer Carbonate (GZ419831)SanofiPhase 3
76
Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tabletBayerPre-clinical
20
Lanthanum Carbonate (Fosrenol, BAY77-1931)BayerPre-clinical
20
Lanthanum Carbonate (BAY77-1931)BayerPhase 2
49